Early use of everolimus for neonatal cardiac rhabdomyoma: a pharmacotherapeutic case with pharmacist-led monitoring
Abstract Cardiac rhabdomyomas (CRHM) are the most common primary cardiac tumors in neonates and are closely linked to tuberous sclerosis complex (TSC). While many tumors regress spontaneously, large or strategically located lesions may require intervention. Everolimus, an mTOR inhibitor, has shown e...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer
2026-05-01
|
| Series: | Saudi Pharmaceutical Journal |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1007/s44446-026-00067-1 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|